Life Sciences: Arresting -- and Enhancing -- the Aging Process October 2, 2007

Life Sciences : Innovations Series
Arresting - and Enhancing -- the Aging Process

Event Sponsor: O'Melveny & Myers LLP

Can we arrest the aging process, offset disease -- and even extend longevity significantly? And, what's the future potential for drugs to treat or prevent a wide variety of diseases related to aging? Join noted aging authority UCSF Professor Cynthia Kenyon, PhD and Elixir Pharmaceuticals CEO William "Bill" Heiden as they provide insights into the current research on aging, discuss the potential for life enhancing changes and share thoughts on the future for new commercial products.

* How recent experiments in mammals hint that similar genetic pathways may affect human aging as well -- and the potential for new drugs
* How disease onset can be offset by preventing cellular damage
* What is the current stage of commercial product development-and what are the enormous unmet needs and the future potential for the development of new drugs

About our Speakers:

Cynthia Kenyon, Ph.D. Herbert BoyerDistinguished Professor of Biochemistry and Biophysics, the University of California, San Francisco.

William "Bill" K. Heidenis, Chief Executive Officer and President of Elixir.

Agenda:
Doors Open 7:30 a.m.
Registration and Breakfast 7:30-8:00
Program 8:00-9:30 a.m
Life Science Innovations Series: The inaugural of a new series initiated by VC Taskforce and sponsored by O'Melveny & Myers. Life Sciences Innovations is designed to enrich the discussions among researchers, entrepreneurs and venture and angel groups about evolving life sciences innovations.

Science Innovations Program Chair:
Kathleen Imhoff, Pacific BioFacilities

If you have any questions please contact
Nat Baker, Direct Phone 415.722.6893

$45 VC Taskforce members; $55 Affiliates; $67 General; (If space is available, door registration is an additional $10).

Official Website: http://www.VCTaskForce.com